Radiation Recall: Another Call With Tamoxifen

Authors

  • Åsa Boström From the Departments of Dermatology, University Hospital, Sweden
  • Gunilla Sjölin-Forsberg Medical Product Agency, Uppsala, Sweden
  • Nils Wilking Oncology Centre, Karolinska Hospital, Stockholm, Sweden
  • Jonas Bergh Oncology Centre, Karolinska Hospital, Stockholm, Sweden

DOI:

https://doi.org/10.1080/028418699432653

Abstract

Tamoxifen, a nonsteroidal antioestrogen, has been used as an adjuvant therapy in patients with oestrogen-receptor positive breast cancer for more than 10 years. Few cutaneous adverse side-effects of the skin are found with this therapy. In this study we present 20 cases of adverse skin effects in relation to tamoxifen during 1979-1997 reported to the Swedish Adverse Drug Reaction Register and 1160 skin side-effects reported to the World Health Organisation's International Collaborative Programme on Drug Monitoring. One new case report of radiation recall in conjunction to tamoxifen, with no sign of reactivation despite 18 months treatment with the tamoxifen analogue toremifene is also discussed in detail. This case illustrates that toremifene can be used as a second-line therapy in patients who have received radiation recall, on tamoxifen.

Downloads

Download data is not yet available.

Downloads

Published

1999-01-01

How to Cite

Boström, Åsa, Sjölin-Forsberg, G., Wilking, N., & Bergh, J. (1999). Radiation Recall: Another Call With Tamoxifen. Acta Oncologica, 38(7), 955–960. https://doi.org/10.1080/028418699432653